Oral anti-viral pill to be ready by the end of this year

New York: The Chief Executive Officer, Albert Bourla of Pfizer, the major pharmaceutical firm of US has announced that the oral anti-viral medicine that the company is producing is in its early stage of trial and is expected to get ready by the end of this year, as per the media.

As per CNBC, the company that was responsible for making the first authorized Covid-19 vaccine in the US in collaboration with BioNTech, the German-based drug maker, started an early-stage clinical trial for testing a new antiviral therapy for coronavirus in the month of March.

The drug belongs to a group of medicine named protease inhibitors and functions by inhibiting an enzyme that is essential for the virus to reproduce in the human cells.

Bourla stated to CNBC, “If clinical trials go well and the Food and Drug Administration (FDA) approves it, the drug could be distributed across the US by the end of the year.”

The report went on to say that protease inhibitors are used in the treatment of other viral pathogens like HIV and hepatitis C.

In the previous month, the pharmaceutical leader advised the US Food and Drug Administration (FDA) to increase the Emergency Use Authorisation (EUA) for its Covid-19 vaccine to include kids within the age group of 12 to 15 years.

Just a day later when Pfizer released data announcing that its vaccine had 100 percent efficacy and very efficient for the younger generation, the plea to expand the emergency use comes up.

Pfizer is also trying to manufacture vaccines for children within the age group of 6 months to 11 years old.

A recent study that found a place in the journal Science, explained that a single jab of the Pfizer manufactured vaccine is capable to boost immunity against the Covid-19 virus but only in people who suffered from this virus previously.

The study concluded that for the people who did not have any record of the previous infection, there can be an insufficiency in the immune response.